个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Cao Qiang[1,2,3] * ; Zhu Jinyi[4] * ; Wu Xinyan[3,5,*1] * ; Li Jiapeng[6] * ; Chen Yuquan[7] ; You Yanwei[8] ; Li Xiaochen[3,9] ; Huang Xufeng[10] ; Zhang Yujie[11] ; Li Rizhu[12] ; Han Dan[1,*2] ;
机构： [1]Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. [2]School of Medicine, Macau University of Science and Technology, 999078, Macau, Macao. [3]Department of Earth Sciences, Kunming University of Science and Technology, 650093, Kunming, China. [4]Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, China. [5]College of Veterinary Medicine, Sichuan Agricultural University, 610000, Chengdu, China. [6]Undergraduate Department, University of Toronto, M2J4A6, Toronto, Canada. [7]Institute of Medical Information/Library, Chinese Academy of Medical Sciences, 100020 Beijing, China. [8]Division of Sports Science & Physical Education, Tsinghua University, Beijing 100084, China. [9]The Third Affiliated Hospital of Shandong First Medical University, Jinan, 250000, Shandong, China. [10]Faculty of Dentistry, University of Debrecen, Debrecen, Hungary. [11]College of Agriculture, Henan University of Science and Technology, 471023, Luoyang, China. [12]Department of Cardiothoracic Surgery, the Affiliated Hospital of Youjiang Medical University for Nationalities, 18 zhongshan 2nd Road, Baise, Guangxi Province, China.
出处：
DOI： 10.7150/jca.92624
ISSN：

关键词： Interleukin-2 Treatment immunotherapy Advanced Non-Small Cell Lung Cancer Intrathoracic Perfusion Chemotherapy Efficacy and Safety Evaluation Retrospective Cohort Study

摘要：
Objective: This study evaluated the efficacy and safety of the gemcitabine and oxaliplatin intrathoracic perfusion chemotherapy (IPCGOR) regimen combined with interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC). Methods: We conducted a retrospective analysis of 460 advanced NSCLC patients from the Yunnan Province Early Cancer Diagnosis and Treatment Project (June 2020-October 2022), assessing the IPCGOR and IL-2 combination. Outcomes were measured based on RECIST 1.1 criteria, focusing on objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (MOS), and treatment safety. Results: The treatment demonstrated an ORR of 67.4%, a DCR of 97.4%, an mPFS of 8.5 months, and an MOS of 12.5 months. 14 patients underwent successful surgery post-treatment. Common adverse reactions were manageable, with no treatment-related deaths reported. Conclusion: The IPCGOR combined with IL-2 regimen shows promising efficacy and a tolerable safety profile for advanced NSCLC. These findings suggest its potential as a reference for treating advanced NSCLC. However, the study's retrospective nature and single-center design pose limitations. Future research should focus on prospective studies, randomized controlled trials, and long-term outcome assessments, particularly in diverse patient subgroups, to further validate and refine the clinical application of this regimen.© The author(s).

基金：
This work was supported by National Natural Science Foundation of China (No. 42267063), Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (No.2022-LCYJ-PY-32); Project of Modern Hospital Management and Development Institute, Aid Project of Nanjing Drum Tower Hospital Health, Education & Research Foundation (No. NDYG2021049), Pharmaceutical Society of Jiangsu Province - Hengrui Hospital Pharmaceutical Foundation Project (H202154).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. [2]School of Medicine, Macau University of Science and Technology, 999078, Macau, Macao. [3]Department of Earth Sciences, Kunming University of Science and Technology, 650093, Kunming, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. [3]Department of Earth Sciences, Kunming University of Science and Technology, 650093, Kunming, China. [5]College of Veterinary Medicine, Sichuan Agricultural University, 610000, Chengdu, China. [*1]College of Veterinary Medicine, Sichuan Agricultural University, 610000, Chengdu, China. Rizhu Li, Department of Cardiothoracic Surgery, the Affiliated Hospital of Youjiang Medical University for Nationalities, 18 zhongshan 2nd Road, Baise, Guangxi Province, China. [*2]Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
推荐引用方式(GB/T 7714)：
Cao Qiang,Zhu Jinyi,Wu Xinyan,et al.Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study[J].Journal Of Cancer.2024,15(7):2024-2032.doi:10.7150/jca.92624.
APA：
Cao Qiang,Zhu Jinyi,Wu Xinyan,Li Jiapeng,Chen Yuquan...&Han Dan.(2024).Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Journal Of Cancer,15,(7)
MLA：
Cao Qiang,et al."Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study".Journal Of Cancer 15..7(2024):2024-2032

相关文献

[1]Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective [2]Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer [3]Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer [4]The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer [5]Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer [6]TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) [7]Radiation Dose Painting with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer [8]Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis [9]The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. [10]with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy

资源点击量：54684 今日访问量：0 总访问量：4646 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号